首页> 美国卫生研究院文献>Oncotarget >TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
【2h】

TERT promoter mutations and telomere length in adult malignant gliomas and recurrences

机译:成人恶性神经胶质瘤的TERT启动子突变和端粒长度及复发

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5–250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03–0.58). Tumors with TERT promoter mutations compared to those without showed increased TERT transcription; we also showed difference in the transcription levels due to the two main mutations. Tumors with TERT promoter mutations had shorter telomeres than those without. The patients with only TERT promoter mutations showed worst survival (median survival 14.6 months) and patients with both IDH and TERT promoter mutations showed best survival (246.5 months). In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004). TERT promoter mutations in low grade gliomas associated with reduced progression free survival (HR 10.2; 95% CI 1.9 – 55.9). While our data affirm the role of TERT promoter mutations in glial tumors, effects on transcription and telomere length emphasise the importance of telomere biology in disease genesis and outcome.
机译:在这份有关303个神经胶质瘤的报告中,我们显示了胶质瘤(80%),其次是少突胶质细胞瘤(70%)和星形细胞瘤(39%)的TERT启动子突变发生率最高。我们观察到少突胶质细胞瘤中TERT启动子与IDH突变之间呈正相关(OR = 26.3; 95%CI 2.5–250.2)与原发性胶质母细胞瘤呈负相关(OR = 0.13; 95%CI 0.03–0.58)。与没有TERT启动子突变的肿瘤相比,具有TERT启动子突变的肿瘤显示出增加的TERT转录。由于两个主要的突变,我们还显示了转录水平的差异。具有TERT启动子突变的肿瘤的端粒比没有肿瘤的端粒短。仅具有TERT启动子突变的患者表现出最差的生存(中位生存14.6个月),同时具有IDH和TERT启动子突变的患者表现出最佳生存(246.5个月)。在星形细胞瘤患者中,TERT启动子突变仅与存活率低有关(P <0.0001); IDH突变和1p / 19q缺失与存活率增加相关(P = 0.0004)。低级神经胶质瘤中的TERT启动子突变与无进展生存期降低相关(HR 10.2; 95%CI 1.9 – 55.9)。尽管我们的数据证实了TERT启动子突变在神经胶质瘤中的作用,但对转录和端粒长度的影响却强调了端粒生物学在疾病发生和结果中的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号